Zynex (ZYXI) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
The annual meeting is scheduled for May 15, 2025, with voting on director elections and auditor ratification.
Proxy materials are distributed primarily via the Internet to reduce costs and environmental impact.
Only shareholders of record as of March 18, 2025, are entitled to vote.
The board recommends voting for all director nominees and for the ratification of the new auditor.
Voting matters and shareholder proposals
Shareholders will vote to elect four directors and to ratify CBIZ CPAs P.C. as the independent auditor for 2025.
Shareholder proposals for the 2026 meeting must be submitted by December 1, 2025.
Voting can be done by mail, phone, or Internet, and a majority of shares is required for a quorum.
Board of directors and corporate governance
The board consists of four members, three of whom are independent under Nasdaq rules.
Committees include Audit, Compensation, and Nominating and Governance, each with formal charters.
The board values diversity in skills and backgrounds and is open to expanding membership.
No family relationships exist among directors and executive officers.
Latest events from Zynex
- Q2 revenue up 11% to $49.9M, but net income fell as expenses and product mix shifted.ZYXI
Q2 20242 Feb 2026 - Sales force productivity and new device launches drive growth, with major FDA milestones ahead.ZYXI
H.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026 - Q3 2024 revenue flat at $50M, 13% order growth, 2024 revenue outlook raised to $200M.ZYXI
Q3 202418 Jan 2026 - Tricare payment suspension led to Q4 loss; cost cuts and new products aim for 2025 recovery.ZYXI
Q4 202425 Dec 2025 - $100 million shelf registration targets growth in pain management and patient monitoring devices.ZYXI
Registration Filing16 Dec 2025 - Shareholders will vote on director elections and auditor ratification at the May 2025 meeting.ZYXI
Proxy Filing1 Dec 2025 - Q1 2025 revenue fell 43% to $26.6M, with cost cuts and new product plans amid TRICARE suspension.ZYXI
Q1 202528 Nov 2025 - Severe revenue decline, $42.9M net loss, and liquidity crisis amid restructuring efforts.ZYXI
Q3 202519 Nov 2025 - Q2 2025 revenue fell 55% and net loss reached $20M amid Tricare suspension and restructuring.ZYXI
Q2 202516 Nov 2025